https://orcid.org/0000-0001-9131-4563
Figures & data
Figure 1 Study design.
Abbreviations: FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure 2 Patient disposition.
Notes:
aLimited to patients with a claim any time in the source claims database. bExcludes data for one patient (considered an extreme outlier).
Abbreviations: FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Abbreviations: FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Table 1 Demographic Characteristics of Patients Initiating LAMA/LABA FDC Treatment (EHR Practice Fusion Patient Cohort)
Table 2 Clinical Characteristics of Patients Initiating LAMA/LABA FDC Treatment
Table 3 Inhaled Therapy Use in the 12 Months Prior to the Index Date
Figure 3 Inhaled medication history (in the 12 months prior to the index date) of patients based on inhaler type.a
Notes:
aPatients could be counted in more than one inhaler category and may have been prescribed additional inhalers/medications for COPD not captured here.Abbreviations: DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; SMI, soft mist inhaler.
Figure 4 Overall pattern of inhaler device use in the 12 months prior to the index date.
Notes:
aPatients could be counted in more than one inhaler category and may have been prescribed additional inhalers/medications for COPD not captured here.Abbreviations: DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; SMI, soft mist inhaler.
Table 4 Healthcare Resource Utilization in the 12 Months Prior to the Index Date